Introduction In recent years, the healthcare industry has witnessed a remarkable transformation with the introduction of telemedicine. It has revolutionized the landscape of weight loss prescriptions. Telemedicine, powered by technological advancements and fueled by the growing need … Read more
Introduction Online prescription weight loss centers have revolutionized the way we approach our health and wellness goals. With convenience and accessibility at the forefront, these centers provide personalized guidance, expert support, and comprehensive approaches to weight loss. … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
Introduction Metabolic weight loss has emerged as a popular approach to shedding unwanted pounds and achieving sustainable weight loss. Unlike traditional weight loss methods that focus solely on calorie restriction, metabolic weight loss emphasizes understanding the intricate … Read more
Introduction to Semaglutide Dosing Semaglutide (the active ingredient in Wegovy® and Ozempic®)[1] is a medication initially developed for the management of type 2 diabetes. Lately, it has emerged as a promising agent in the realm of weight … Read more
Introduction An online weight loss prescription has emerged as a convenient an accessible option for individuals seeking professional guidance in their weight loss journey. In recent years, these virtual platforms have gained significant popularity. Their convenience, ease … Read more
FDA notice on Zepbound™/Mounjaro® shortage: The U.S. Food and Drug Administration has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Schedule a visit with an Ivim provider to discuss what this … Read more
Liraglutide (the active ingredient in Saxenda®)[1] and semaglutide (the active ingredient in Wegovy® and Ozempic®)[2] are both medications that belong to the same class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. Saxenda® (liraglutide), Wegovy® (semaglutide) is … Read more
Obesity is a growing health concern worldwide, and it is associated with an increased risk of developing several chronic diseases, including type 2 diabetes, heart disease, and certain types of cancer. While diet and exercise are the … Read more
Liraglutide (the active ingredient in Saxenda®)[1] and semaglutide (the active ingredient in Wegovy® and Ozempic®)[2] are two GLP-1 receptor agonists used to manage type 2 diabetes. The primary difference between the two GLP-1 medications is the dosage … Read more
